Gemtesa

Overactive Bladder Syndrome
Treatment
20 Active Studies for Gemtesa

What is Gemtesa

VibegronThe Generic name of this drug
Treatment SummaryVibegron is a medication used to treat overactive bladder in adults. It works by relaxing the muscle of the bladder to increase bladder capacity. Vibegron is the second type of drug in its class to be approved for this purpose, following Mirabegron, which was approved in 2012. Vibegron is less likely to interact with other drugs, making it a safer choice for patients. It is available as an oral tablet brand called GEMTESA.
Gemtesais the brand name
image of different drug pills on a surface
Gemtesa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gemtesa
Vibegron
2020
1

Effectiveness

How Gemtesa Affects PatientsVibegron is a drug that helps improve symptoms of an overactive bladder. It works by increasing the size of the bladder and slowing down bladder contractions, so that people can go longer between bathroom trips. Clinical studies in Japanese patients with overactive bladders showed that vibegron improved the frequency of bathroom trips, urgency, and urgency incontinence episodes. Compared to other beta-receptors, vibegron is much more selective for beta-3 receptors, which makes it more effective for treating overactive bladders.
How Gemtesa works in the bodyOveractive bladder is caused by poor communication between the bladder and the brain, leading to abnormal bladder sensations. Vibegron is a medication that helps treat overactive bladder by interacting with beta-3 adrenaline receptors. This interaction stimulates the formation of cyclic adenosine monophosphate, which helps relax the muscles of the bladder and reduce the urge to urinate. Vibegron also works by affecting sensory mechanisms without directly affecting the bladder muscles.

When to interrupt dosage

The encouraged measure of Gemtesa relies upon the confirmed condition. The amount of dosage changes, as per the administration procedure featured in the below-listed table.
Condition
Dosage
Administration
Overactive Bladder Syndrome
75.0 mg,
Tablet, film coated, Tablet, film coated - Oral, Oral,

Warnings

Gemtesa has one counterindication, and it should not be administered while having any of the conditions in the following table.Gemtesa Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Vibegron may interact with Pulse Frequency
There are 5 known major drug interactions with Gemtesa.
Common Gemtesa Drug Interactions
Drug Name
Risk Level
Description
Acetyldigoxin
Moderate
The serum concentration of Acetyldigoxin can be increased when it is combined with Vibegron.
Benzylpenicilloyl polylysine
Moderate
Vibegron may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Digoxin
Moderate
The serum concentration of Digoxin can be increased when it is combined with Vibegron.
Formoterol
Moderate
Vibegron may increase the sympathomimetic activities of Formoterol.
Metildigoxin
Moderate
The serum concentration of Metildigoxin can be increased when it is combined with Vibegron.
Gemtesa Toxicity & Overdose RiskIf a vibegron overdose is suspected, supportive and symptomatic treatments should be started. There is not a lot of information available about overdosing on vibegron.
image of a doctor in a lab doing drug, clinical research

Gemtesa Novel Uses: Which Conditions Have a Clinical Trial Featuring Gemtesa?

32 active trials are in progress to assess the efficacy of Gemtesa in providing symptomatic relief for Overactive Bladder Syndrome.
Condition
Clinical Trials
Trial Phases
Overactive Bladder Syndrome
29 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2

Gemtesa Reviews: What are patients saying about Gemtesa?

5Patient Review
1/17/2022
Gemtesa for Needing to Urinate Immediately
I saw a great response on the second day of taking this pill. I take it alongside a diuretic and it's helped me to better control my bathroom needs.
5Patient Review
10/9/2021
Gemtesa for Overactive Bladder
After using this medication for just a week, I found it to be more effective than other treatments I've tried in the past for my OAB.
4.3Patient Review
1/26/2022
Gemtesa for Overactive Bladder
This medication was effective for me when I first started using it; however, now my symptoms have returned and I am not getting the same relief.
4Patient Review
7/2/2021
Gemtesa for Overactive Bladder
So far, I've been using this for two days and it has definitely cut down on how often I have to go to the bathroom. But now I'm starting to worry that I might be retaining urine. Is there any way to tell?
3.3Patient Review
11/5/2022
Gemtesa for Urine Leakage When there is a Strong Desire to Void
When I first started taking this medication, I was amazed at how well it worked. There were no more accidents or issues with my overactive bladder. However, I suddenly developed terrible diarrhea and other Irritable Bowel Syndrome symptoms, so I had to stop taking it.
3Patient Review
6/12/2022
Gemtesa for Overactive Bladder
This medication caused my feet to swell and made it difficult to urinate. I stopped taking it immediately after consulting with a urologist, as this is a known side effect of the drug.
3Patient Review
8/23/2022
Gemtesa for Overactive Bladder
Initially, this medication helped me a lot with my overactive bladder. However, it stopped being effective after a few months and made my sinus problems worse. Once I stopped taking it, I felt much better.
2.7Patient Review
6/20/2022
Gemtesa for Overactive Bladder
I experienced constipation after taking this medication for just a few days. This is a common side effect of many medications, but this one is very expensive (over $500 per month) and not covered by insurance.
2.7Patient Review
3/31/2022
Gemtesa for Overactive Bladder
I haven't seen any improvement in my urge incontinence since starting this medication. I'm extremely disappointed.
2.3Patient Review
4/15/2022
Gemtesa for Overactive Bladder
Even when taking Gemtessa regularly, I experienced a lot of urinary accidents. The drug also caused my feet to swell. Overall, not a great experience.
2Patient Review
1/13/2022
Gemtesa for Overactive Bladder
While this medication did work to stop my OAB symptoms, after taking it for 2 weeks my whole body and scalp were itching. I began losing TONS of hair every day. Like handfuls of hair were suddenly falling out. As soon as I realized it was the medication, I stopped taking it and my hair loss also slowed down almost immediately. Be very careful with this medication!
2Patient Review
6/17/2022
Gemtesa for Overactive Bladder
My mother experienced urine retention after taking this medication for two months and was then admitted to the hospital due to acute kidney disease. She is now using a catheter and stopped taking the medication on 6/11/22. If anyone has any information about how long it will take for her to urinate again, please let me know as the urologist was unable to give me a straight answer.
2Patient Review
7/2/2022
Gemtesa for Overactive Bladder
This medication unfortunately made my condition worse. I had to stop taking it and go back to Vesicare.
1Patient Review
7/19/2022
Gemtesa for Overactive Bladder
This medication was great for the first week, but then the constipation I experienced was unbearable. The medication stopped working after that. I stuck it out for about four months, switched back to Myrbetriq, and the constipation is gone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gemtesa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of GEMTESA?

"A headache, a UTI, a runny or stuffy nose, diarrhea, nausea, and an upper respiratory tract infection can all be symptoms of the flu."

Answered by AI

How quickly does GEMTESA work?

"Gemtesa begins working after you take your first dose of medication. In clinical studies, people had decreased urinary incontinence, urgency, and frequency within 12 weeks."

Answered by AI

Is GEMTESA better than Myrbetriq?

"The beta-3 agonist class of medication (which includes Gemtesa) has numerous advantages over the anti-cholinergic class of medications (Detrol, Ditropan, VESIcare, Enablex, Sanctura, Toviaz) in terms of simple dosing, ability to crush, no worries about blood pressure, and less drug-drug interactions."

Answered by AI

What is GEMTESA prescribed for?

"This sudden urge can happen even when your bladder is not full.

This medication is used in order to treat an overactive bladder. An overactive bladder is a problem where your bladder cannot store urine properly, resulting in a sudden urge to urinate even when your bladder is not full."

Answered by AI

Clinical Trials for Gemtesa

Image of Stanford Medicine Department of Obstetrics & Gynecology in Palo Alto, United States.

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder

22 - 80
Female
Palo Alto, CA
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.
Waitlist Available
Device
Stanford Medicine Department of Obstetrics & Gynecology (+10 Sites)Mickey Karram, MDInMode MD Ltd.
Have you considered Gemtesa clinical trials? We made a collection of clinical trials featuring Gemtesa, we think they might fit your search criteria.Go to Trials
Have you considered Gemtesa clinical trials? We made a collection of clinical trials featuring Gemtesa, we think they might fit your search criteria.Go to Trials
Image of UConn Health in Farmington, United States.

MitoQ for Lower Urinary Tract Symptoms

50 - 75
Female
Farmington, CT
The goal of this clinical trial is to test the effect of a supplement called MitoQ (mitoquinol mesylate) on bladder symptoms such as urgency and frequency in women 50 years and older who have the metabolic syndrome. The main questions it aims to answer are: * Is the study design feasible and acceptable to participants? * Do participants taking the study drug get any improvement to their bladder symptoms compared to participants taking a placebo (a look-alike substance that contains no drug)? Participants will take 2 capsules of the study drug every morning for 4 months, answer many questions about their health including questions about their bladder health, perform physical and cognitive testing, give blood and urine samples, collect urine over 24 hour periods 3 times over the 4 months of the study, complete 3 day bladder diaries about how much they drink and void, undergo electrocardiograms, have their vitals and measurements (weight, height, waist circumference) taken, participate in 4 visits to the clinical research area and participate in many phone calls of varying length. Researchers will compare participants who were taking capsules containing MitoQ and participants taking capsules not containing MitoQ to see if MitoQ improves their bladder symptoms (urgency, frequency, nocturia, incontinence, etc.)
Phase 2
Recruiting
UConn HealthIman M Al-Naggar, PhD
Image of Mickey Karram MD in Corona Del Mar, United States.

Nerve Ablation for Overactive Bladder

21 - 80
Female
Corona Del Mar, CA
The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. \[Time Frame: 3 months\] Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis. Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.
Waitlist Available
Has No Placebo
Mickey Karram MD (+2 Sites)Mickey Karram, MDInMode MD Ltd.
Image of University of Chicago in Chicago, United States.

Sacral Neuromodulation for Urge Incontinence

18+
Female
Chicago, IL
Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a \> 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.
Recruiting
Has No Placebo
University of ChicagoKimberly Kenton, MD
Have you considered Gemtesa clinical trials? We made a collection of clinical trials featuring Gemtesa, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security